
|Videos|September 22, 2016
Metastatic Lung Cancer with Jared M. Weiss, MD: Case 1
Metastatic Lung Cancer with Jared M. Weiss, MD
Advertisement
Weiss case 1:
A 65-year-old man with stage IV NSCLC.
- Tissue biopsy showed EGFR+ adenocarcinoma
- The patient was enrolled in a clinical trial of erlotinib vs erlotinib/bevacizumab
- He was treated with erlotinib for 10 months before developing asymptomatic progression, with slowly growing lesions.
- He was continued on erlotinib for 3 more months; His next scan showed rapid progression.
- Repeat bronchoscopy and mutation testing showed an acquired EGFR T790M mutation
- Patient was subsequently switched to osimertinib
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5






































